Syngene International Limited
Syngene was established in 1994 as a subsidiary of Biocon Limited, India's largest biopharmaceutical company. Since then, Syngene has grown to become one of the largest and most diversified contract research and manufacturing organizations in Asia, with over 4500 scientists and staff, and a state-of-the-art research campus spread over 200 acres in Bengaluru. In 2022, Syngene International’s revenue was approximately INR 3,000 crores.
Syngene's extensive range of capabilities encompasses various domains, including small molecule and biologics discovery and development, analytical and formulation development, clinical development, safety assessment, and custom synthesis and manufacturing. Additionally, Syngene has established specialized centers of excellence for therapeutic areas including oncology, immunology, ophthalmology, metabolic diseases, and infectious diseases.
Syngene prioritizes innovation and excellence in science, as evidenced by its impressive track record. The company has filed over 140 patents and published over 300 peer-reviewed papers in esteemed journals. Furthermore, Syngene has also received numerous awards and recognitions for its exceptional achievements in contract research and manufacturing.
Syngene is a publicly listed company on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE) since 2015. Syngene has a market capitalization of over $3 billion as of May 2023. Syngene's vision is to be a global leader in innovation-led scientific services that enable better health outcomes for patients worldwide.
Foundation: 1994
Headquarters: Bengaluru, Karnataka
Website: https://www.syngeneintl.com/
